{"slug": "what-big-pharma-s-q2-results-tell-us", "title": "What Big Pharma's Q2 Results Tell Us", "summary": "Big Pharma's second-quarter earnings calls highlighted the growing role of AI in drug development and the intensifying oral GLP-1 competition between Novo Nordisk and Eli Lilly, alongside leadership changes at Sarepta and Sanofi, reflecting an industry at a pivotal moment of opportunity and challenge.", "body_md": "Earnings calls are a chance to catch up with the latest developments across Big Pharma and beyond, and last quarter was no different. From the rollout of AI to the oral GLP-1 battle between Novo Nordisk and Eli Lilly and new leadership at Sarepta and Sanofi, it feels like the opportunities and challenges for biopharma have never been greater.", "url": "https://wpnews.pro/news/what-big-pharma-s-q2-results-tell-us", "canonical_source": "https://www.realclearhealth.com/2026/08/24/what_big_pharmas_q2_results_tell_us_1202088.html", "published_at": "2026-08-24 13:25:36+00:00", "updated_at": "2026-08-24 13:42:56.902030+00:00", "lang": "en", "topics": ["artificial-intelligence"], "entities": ["Novo Nordisk", "Eli Lilly", "Sarepta", "Sanofi"], "alternates": {"html": "https://wpnews.pro/news/what-big-pharma-s-q2-results-tell-us", "markdown": "https://wpnews.pro/news/what-big-pharma-s-q2-results-tell-us.md", "text": "https://wpnews.pro/news/what-big-pharma-s-q2-results-tell-us.txt", "jsonld": "https://wpnews.pro/news/what-big-pharma-s-q2-results-tell-us.jsonld"}}